Evidence/Findings:
<p>Based on record review and interview, the manager failed to ensure that a medication administered to a resident was administered in compliance with a medication order, for two of six residents sampled. The deficient practice posed a risk if the resident experienced a change in condition due to improper administration of medication.</p><p><br></p><p>Findings include: </p><p><br></p><p>1. A review of R4's medical record revealed a medication order, dated February 4, 2025, for Gabapentin 300 milligrams (mg), one capsule by mouth (PO) twice a day (bid). </p><p><br></p><p>2. A review of R4's medication administration record (MAR) for October 2025 revealed Gabapentin 300 mg was held due to "pending delivery" on the following dates and times: </p><ul><li>October 2, 2025 - October 4, 2025 at 8:00 PM; </li><li>October 5, 2025, at 8:00 AM and 8:00 PM; </li><li>October 6, 2025, at 8:00 PM; </li><li>October 7, 2025, at 8:00 AM; </li><li>October 9, 2025, at 8:00 AM; and</li><li>October 10, 2025 - October 12, 2025 at 8:00 PM. </li></ul><p><br></p><p>3. A review of R4's MAR for October 2025 revealed Gabapentin 300 mg was administered on the following dates and times:</p><ul><li>October 6, 2025, at 8:00 AM;</li><li>October 7, 2025, at 8:00 PM;</li><li>October 8, 2025, at 8:00 AM and 8:00 PM; and</li><li>October 9, 2025, at 8:00 PM.</li></ul><p><br></p><p>4. In an interview, E1 reported R4's medications were available for administration as of October 2, 2025.</p><p><br></p><p>5. A review of R5's medical record revealed medication orders for the following medications:</p><ul><li>Atorvastatin Calcium 40 mg, 1 tablet po at bedtime (qhs);</li><li>Mometasone Furoate 50 micrograms (mcg), 2 sprays into each nostril every day (qd);</li><li>Myrbetriq 25 mg, 1 tablet po qd;</li><li>Prednisone 1 mg, 3 tablets po qd;</li><li>Pregabalin 100 mg, 1 capsule po bid;</li><li>Pregabalin 75 mg, 1 capsule po bid; and</li><li>Spironolactone 50 mg, 1 tablet po qd.</li></ul><p><br></p><p>6. A review of R5's MAR for October 2025 revealed <span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">Atorvastatin Calcium 40 mg was held</span> due to "pending delivery" October 5, 2025 - October 10, 2025, at 8:00 PM.</p><p><br></p><p>7. A review of R5's MAR for October 2025 revealed <span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">Atorvastatin Calcium 40 mg was administered October 3, 2025 - October 4, 2025, at 8:00 PM. </span></p><p><br></p><p>8. A review of R5's MAR for October 2025 revealed Mometasone Furoate 50 mcg was held October 11, 2025, at 8:00 AM for "pending delivery."</p><p><br></p><p>9. A review of R5's MAR for October 2025 revealed <span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">Myrbetriq 25 mg was held October 7, 2025, at 8:00 AM for "pending delivery."</span></p><p><br></p><p><span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">10. A review of R5's MAR for October 2025 revealed Prednisone 1 mg was held October 7, 2025, at 8:00 AM for "pending delivery."</span></p><p><br></p><p><span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">11. A review of R5's MAR for October 2025 revealed Pregabalin 100 mg was held on the following dates for "duplicate":</span></p><ul><li>October 5, 2025, at 8:00 AM;</li><li>October 8, 2025 - October 10, 2025, at 8:00 AM and 8:00 PM;</li><li>October 11, 2025, at 8:00 AM; and</li><li>October 14, 2025.</li></ul><p>However, R5's medication orders revealed two orders for Pregabalin.</p><p><br></p><p>12. A review of R5's MAR for October 2025 revealed Pregabalin 75 mg was held on the following dates for "duplicate":</p><ul><li>October 3, 2025 - October 6, 2025, at 8:00 PM;</li><li>October 7, 2025, at 8:00 AM and 8:00 PM;</li><li>October 12, 2025, at 8:00 AM;</li><li>October 13, 2025, at 8:00 AM and 8:00 PM; and</li><li>October 14, 2025, at 8:00 AM.</li></ul><p><span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">However, R5's medication orders revealed two orders for Pregabalin. </span></p><p><br></p><p><span style="background-color: rgb(255, 255, 255); color: rgb(68, 68, 68);">13. A review of R5's MAR for October 2025 revealed Spironolactone 50 mg was held on October 5, 2025, due to "pending."</span></p><p><br></p><p>14. In an interview, E1 reported a full medication audit was performed for R5 on October 2, 2025, and all medications were available.</p><p><br></p><p>15. In an exit interview, the findings were reviewed with E1, and no additional information was provided.</p><p><br></p><p>This is a repeat deficiency from the complaint inspection conducted on August 1, 2024, and the compliance and complaint inspection conducted on January 16, 2025.</p>
Summary:
The following deficiencies were found during the on-site investigation of complaints 00147436, 00146895, 00144382, 00143408, 00138894, 00144250, and 00147612 conducted on October 14, 2025: